Cerenome Completes Patient Enrollment in REYOBIQ Phase 2 Study
Cerenome completed patient enrollment in its Phase 2 study of REYOBIQ for recurrent glioblastoma.
Related stories
Innovotech Secures $600,000 in Credit Facilities From ATB Financial
Innovotech said it established a banking partnership with ATB Financial, securing $600,000 in credit facilities to support growth.
M impact | EQUITY | Oct 29, 2026, 11:55 PM UTC
Mastercard quarterly profit tops estimates
Reuters reports Mastercard's quarterly profit exceeded expectations, citing resilient consumer spending.
M impact | EQUITY | Oct 29, 2026, 11:54 PM UTC
Vale Reports Record Third-Quarter Production at Salobo
Vale reported record production for a third quarter at Salobo.
L impact | EQUITY | Oct 29, 2026, 11:54 PM UTC
Vale Q3 Iron Ore Production Falls 6%
Vale said third-quarter iron ore production fell 6%.
M impact | EQUITY | Oct 29, 2026, 11:53 PM UTC
Frontera Energy Announces Third-Quarter 2026 Results Conference Call
M impact | EQUITY | Oct 29, 2026, 11:51 PM UTC
Frontera Energy Announces Third-Quarter 2026 Results Call
M impact | EQUITY | Oct 29, 2026, 11:51 PM UTC